{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:42:16Z","timestamp":1790718136265,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40265-015-0468-9","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T06:10:13Z","timestamp":1442556613000},"page":"1669-1678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Eliglustat: A Review in Gaucher Disease Type 1"],"prefix":"10.1007","volume":"75","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"issue":"4 Suppl 2","key":"468_CR1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jpeds.2009.07.004","volume":"155","author":"AM Martins","year":"2009","unstructured":"Martins AM, Valadares ER, Porta G, et al. Recomendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl 2):S10\u20138.","journal-title":"J Pediatr."},{"issue":"5","key":"468_CR2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","volume":"13","author":"RY Wang","year":"2011","unstructured":"Wang RY, Bodamer OA, Watson MS, et al. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011;13(5):457\u201384.","journal-title":"Genet Med."},{"key":"468_CR3","unstructured":"Genzyme Corporation. Cerezyme\u00ae imiglucerase for injection: US prescribing information. 2011. www.cerezyme.com\/ . Accessed 5 Aug 2015."},{"key":"468_CR4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation.V2012.1.13.3797921","volume":"2012","author":"GA Grabowski","year":"2012","unstructured":"Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13\u20135.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"468_CR5","unstructured":"European Medicines Agency. Cerdelga: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/ . Accessed 8 June 2015."},{"issue":"5","key":"468_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swen JJ, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402\u20138.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"468_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","volume":"91","author":"KA McEachern","year":"2007","unstructured":"McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259\u201367.","journal-title":"Mol Genet Metab."},{"issue":"3","key":"468_CR8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","volume":"33","author":"J Marshall","year":"2010","unstructured":"Marshall J, McEachern KA, Chuang WL, et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010;33(3):281\u20139.","journal-title":"J Inherit Metab Dis."},{"key":"468_CR9","unstructured":"Genzyme Ireland Ltd. Cerdelga\u00ae (eliglustat) capsules, for oral use: US prescribing information. 2014. http:\/\/www.cerdelga.com\/ . Accessed 8 June 2015."},{"issue":"5","key":"468_CR10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","volume":"51","author":"MJ Peterschmitt","year":"2011","unstructured":"Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695\u2013705.","journal-title":"J Clin Pharmacol."},{"issue":"7","key":"468_CR11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706.","journal-title":"JAMA."},{"issue":"9985","key":"468_CR12","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355\u201362.","journal-title":"Lancet."},{"issue":"6","key":"468_CR13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893\u20139.","journal-title":"Blood."},{"issue":"4","key":"468_CR14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","volume":"53","author":"E Lukina","year":"2014","unstructured":"Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4\u00a0years of treatment. Blood Cells Mol Dis. 2014;53(4):274\u20136.","journal-title":"Blood Cells Mol Dis."},{"issue":"10","key":"468_CR15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","volume":"43","author":"RS Kamath","year":"2014","unstructured":"Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014;43(10):1353\u201360.","journal-title":"Skeletal Radiol."},{"issue":"20","key":"468_CR16","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095\u20138.","journal-title":"Blood."},{"issue":"2","key":"468_CR17","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.ymgme.2014.12.207","volume":"114","author":"MJ Peterschmitt","year":"2015","unstructured":"Peterschmitt MJ, Taylor JS, Angell J, et al. Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: post-hoc comparison to imiglucerase in a real-world setting [abstract]. Mol Genet Metab. 2015;114(2):S93.","journal-title":"Mol Genet Metab."},{"key":"468_CR18","unstructured":"Giraldo P, Pleat R, Angell J, et al. Stability is maintained in adult patients with Gaucher disease type 1 (GD1) switched from velaglucerase alfa to eliglustat: a sub-analysis of the eliglustat, phase 3 ENCORE trial [abstract no. P-610]. J Inherit Metab Dis. 2015;38(Suppl 1):S296\u20137."},{"issue":"2","key":"468_CR19","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ymgme.2014.12.179","volume":"114","author":"P Mistry","year":"2015","unstructured":"Mistry P, Amato DJ, Dasouki M, et al. ENGAGE - a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18\u00a0months [abstract]. Mol Genet Metab. 2015;114(2):S81\u20132.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"468_CR20","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.ymgme.2014.12.058","volume":"114","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman GI, Cravo R, et al. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]. Mol Genet Metab. 2015;114(2):S33\u20134.","journal-title":"Mol Genet Metab."},{"issue":"Suppl 5","key":"468_CR21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts JM, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(Suppl 5):4\u201314.","journal-title":"Semin Hematol."},{"issue":"2","key":"468_CR22","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ymgme.2013.12.218","volume":"111","author":"L Ross","year":"2014","unstructured":"Ross L, Peterschmitt J, Puga AC, et al. Eliglustat safety profile based on a pooled analysis of data from four trials in Gaucher disease type I [abstract]. Mol Genet Metab. 2014;111(2):S90.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"468_CR23","first-page":"S69","volume":"114","author":"H Lau","year":"2015","unstructured":"Lau H, Ibrahim J, Peterschmitt MJ, et al. Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]. Mol Genet Metab. 2015;114(2):S69\u201370.","journal-title":"Mol Genet Metab."},{"key":"468_CR24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","volume":"136","author":"D Hughes","year":"2007","unstructured":"Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of haematological and onco-haematological aspects of Gaucher disease. Brit J Haematol. 2007;136:676\u201386.","journal-title":"Brit J Haematol."},{"issue":"Suppl 5","key":"468_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1; revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(Suppl 5):15\u201322.","journal-title":"Semin Hematol."},{"key":"468_CR26","unstructured":"European Medicines Agency. Zavesca 100\u00a0mg hard capsules: summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/ . Accessed 26 June 2015."},{"key":"468_CR27","unstructured":"Actelion Pharmaceuticals US Inc. Zavesca\u00ae (miglustat) capsules, for oral use: US prescribing information. 2014. http:\/\/www.zavesca.com\/ . Accessed 26 June 2015."},{"issue":"8","key":"468_CR28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35(8):613\u201320.","journal-title":"Drugs Future."},{"issue":"7","key":"468_CR29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","volume":"55","author":"JA Shayman","year":"2014","unstructured":"Shayman JA, Larsen SD. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. J Lipid Res. 2014;55(7):1215\u201325.","journal-title":"J Lipid Res."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0468-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0468-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0468-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T08:39:42Z","timestamp":1599554382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0468-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":29,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0468-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}